Despite the slightly warmer weather and longer periods of sunshine, we are still in the depths of cold and flu season, a ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

New figures show the number of babies admitted to hospital with respiratory viruses has trebled in just a year, according to Manx Care.

covering the critical winter RSV season. Uptake of the nirsevimab program so far in Ireland has been high, with 83 percent of eligible infants receiving the treatment. These results have spurred ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

RSV is a common, but highly infectious ... He said while most babies and children do not need hospital treatment, the younger the child, the more likely it is for them to need hospitalisation ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

7. New RSV prevention options for infants and pregnant mothers A new RSV prevention option for infants was introduced in 2023: the monoclonal antibody treatment Beyfortus (nirsevimab). This shot is ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led to a tenfold increase in the number of infants in that group that ...